RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Stepped up their Corporate Presentation GameVery interesting find. I noticed two things. Seems to be a tacit acceptance of adaptive trials with interim reads given there's nothing out there. And this was written in 2016, so I would assume that prediliection is still there. Second, whole first section under considerations is SAFETY and damage to liver. That seems to count an awful lot for regulators, and should in the THTX plan I would think.